法国临床效益评价对我国创新药医保目录动态调整的启示
|
摘要
通过介绍法国的临床效益评价,尤其是法国临床效益评价结果对医保准入的影响,进而选取典型案例阐述如何做出具体品种的评价结果和如何据此做出医保准入决定,以期为我国创新药医保目录动态调整提供思路与启示。
It mainly introduced the clinical benefit evaluation of France, and focused on the impact of clinical benefit evaluation results on medical insurance access. On this basis, the typical cases were selected to explain how to make the evaluation results of specific varieties and how to make medical insurance access decisions accordingly so as to provide ideas and enlightenment for the dynamic adjustment of medical insurance catalogue for innovative medicine in China.
It mainly introduced the clinical benefit evaluation of France, and focused on the impact of clinical benefit evaluation results on medical insurance access. On this basis, the typical cases were selected to explain how to make the evaluation results of specific varieties and how to make medical insurance access decisions accordingly so as to provide ideas and enlightenment for the dynamic adjustment of medical insurance catalogue for innovative medicine in China.
引文
[1] FRANKENA M. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries[J]. Health policy, 2015(119):195-202.
[2]沈秋欢.药品参考价格制度典型国家创新药品定价与补偿机制[J].中国新药杂志,2017,26(14):1612-1617.
[3]SERMET C, ANDRIEU V, GODMAN B, et al. Ongoing pharmaceutical reforms in France:implications for key stakeholder groups[J]. Appl health econ health policy, 2010,8(1):7-24.
[4]卢碧香,关轶茹,张方.法国药品临床疗效和临床疗效改善评级管理及其借鉴启示[J].中国药物应用与监测,2018,15(2):113-117.
[5] SZERB A, KANAVOS P. Health technology assessment of cancer drugs in France and Germany:commonalities and differences in the value assessment of medical technologies[EB/OL].(2015-01)[2018-09-18] http://www.lse.ac.uk/lse-health/assets/documents/working-paper-series/LSEHWP43.pdf.
[2]沈秋欢.药品参考价格制度典型国家创新药品定价与补偿机制[J].中国新药杂志,2017,26(14):1612-1617.
[3]SERMET C, ANDRIEU V, GODMAN B, et al. Ongoing pharmaceutical reforms in France:implications for key stakeholder groups[J]. Appl health econ health policy, 2010,8(1):7-24.
[4]卢碧香,关轶茹,张方.法国药品临床疗效和临床疗效改善评级管理及其借鉴启示[J].中国药物应用与监测,2018,15(2):113-117.
[5] SZERB A, KANAVOS P. Health technology assessment of cancer drugs in France and Germany:commonalities and differences in the value assessment of medical technologies[EB/OL].(2015-01)[2018-09-18] http://www.lse.ac.uk/lse-health/assets/documents/working-paper-series/LSEHWP43.pdf.